TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02269449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 6Fr Glidesheath Slender sheath
Description: 6Fr sheath (Glidesheath slender: GSS), which is characterized with the same inner lumen diameter with contemporary 6Fr sheath as well as the sheath outer diameter similar with contemporary 5Fr sheath.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5Fr sheath
Description: 5Fr Hydrophilic coating sheath from Terumo.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemostasis with TR band
Description: Hemostasis is achieved using TR band (TERUMO) Patent hemostasis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Any hemostasis procedure
Description: Hemostasis is achieved by any hemostasis of each hospital's routine procedure.
Study: NCT00574951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: motesanib diphosphate
Study: NCT01791400

Intervention type: DRUG
Group type: OTHER
Intervention: metoclopramide, injection,20mg, one time
Description: metoclopramide, intravenous injection,20mg, one time
Study: NCT00810927

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Doppler flowmetry
Description: Measurement of choroidal blood flow

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Doppler flowmetry
Description: Measurement of choroidal blood flow

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Laser Doppler flowmetry
Description: Measurement of choroidal blood flow

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of intraocular pressure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of intraocular pressure

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Measurement of intraocular pressure
Study: NCT03324581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-64005
Description: OPC-64005 film coated tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: Atomoxetine gelatin capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: OPC-64005-matching placebo film coated tablets and atomoxetine-matching placebo gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: OPC-64005-matching placebo film coated tablets and atomoxetine-matching placebo gelatin capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: OPC-64005-matching placebo film coated tablets and atomoxetine-matching placebo gelatin capsules
Study: NCT01791400

Intervention type: DRUG
Group type: OTHER
Intervention: Sumatriptan, injection, 6 mg, one time
Description: Sumatriptan, subcutaneous injection, 6 mg, one time
Study: NCT01203176

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopic polypectomy
Description: Hysteroscopy is a well established minimally invasive surgery method for diagnostic and intervention operations inside the uterine cavity. Using this method one can observe the endometrium and remove polyps.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysteroscopic polypectomy
Description: Hysteroscopy is a well established minimally invasive surgery method for diagnostic and intervention operations inside the uterine cavity. Using this method one can observe the endometrium and remove polyps.
Study: NCT03696927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Powered Prosthesis (APEX) for Spinal Cord Injury
Description: The Active Powered Prosthesis (APEX) is a proof-of-concept shoulder-elbow-wrist device intended to provide non-invasive active powered robotic assistive movement to upper extremities. Focus group participants will control the APEX device on a test manikin and provide feedback on the device design and function.
Study: NCT03518671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy, face to face
Description: self-limited cognitive behavioral therapy delivered weekly for 6 weeks via face-face delivery method

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy, telemedicine
Description: self-limited cognitive behavioral therapy delivered weekly for 6 weeks via tablet-based telemedicine platform
Study: NCT01165736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-05186462
Description: single intravenous infusion of 100 microgram
Study: NCT03914014

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue manipulation
Description: From the estimated date of ovulation to the onset of menstrual bleeding, connective tissue massage will be applied to the sacral, lumbar, lower thoracic and anterior pelvic regions for 5 days per week. The application will take 10 min. During the massage treatment, the physiotherapist will touch the end of the middle finger with the skin of the patient and apply the skin to the pull. The patient will be in the supine position during the treatment of the anterior pelvic region while the patient is in the sitting position during the treatment of the back area.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo ultrasound
Description: From the estimated date of ovulation to the beginning of the next menstrual bleeding, placebo ultrasound will be applied a total of 10 minutes (5 minutes for sacral and lumbar, and lower thoracic regions and 5 min for the anterior pelvic region). Placebo ultrasound application will be performed with superficial circular movements without applying excessive pressure. During the application, the device will only be switched on, the dose will not be adjusted and the patient will be given an image of ultrasound dose.
Study: NCT03588000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthen self-monitoring of blood glucose
Description: Strengthen self-monitoring of blood glucose by Internet mobile terminal（APP）.
Study: NCT03479346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GGT
Description: Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
Study: NCT01215240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis
Description: Prophylactic peritoneal dialysis
Study: NCT03912805

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin, Type A
Description: topical liniment

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Formulation
Study: NCT01093885

Intervention type: DRUG
Group type: OTHER
Intervention: Ambrisentan
Description: Drug is dispensed in tablet form. Ambrisentan with anti-fibrotic to assess benefit on skin~Dosing of ambrisentan will begin at 5mg daily for the first month. Half the patients will remain at 5mg daily, while the remaining patients will be increased to a maintenance dose of 10mg daily on the fourth week.
Study: NCT00598481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan is used for non-myeloablative conditioning
Study: NCT02778282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MySafeRx™
Description: The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
Study: NCT04008030

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Specified dose on specified days
Study: NCT00657501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone gel
Description: once daily transdermal gel, 300 mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: once daily transdermal placebo gel
Study: NCT04008030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT03416504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gradual Exposure (EXP-G)
Description: In EXP-G, exposure proceeded hierarchically from mildly, to moderately, to highly intense stimuli so that exposure intensity gradually built between (but not within) sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Variable Exposure (EXP-V)
Description: In EXP-V, exposure stimuli were chosen at random (i.e., pieces of paper with exposure stimuli written on them were pulled randomly from an opaque container) so that mild, moderate, and high intensity exposures could occur in any order during any of the sessions (the participant was not informed which level was coming next). This aimed to maximize (a) uncertainty, (b) variability in exposure intensity, and (c) variability in corresponding physiological arousal.
Study: NCT03395938

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Proactive engagement
Description: The engagements would include (1) a sealed envelope containing a cancer information sheet and an invitation letter directed towards siblings for them to contact the research team, (2) weekly phone reminders to the participants for a total of 4 weeks in a bid to remind participants of the need to convey the screening message to their siblings. The envelope will contain information on the various means for the siblings to contact the research team. These include communication means such as electronic mails (emails), telephone, hard copy returned mails through pre-paid envelopes, short messaging services (SMSs) or clinic consult.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Current practice
Description: This intervention depicts current practices by having the research team educate the participants on the Ministry of Health Singapore screening guidelines akin to counselling sessions carried out during the patient's clinical consultation. The research team would highlight that we would be happy to assist if necessary. The research team would then contact the patients in 4 weeks to check if they have communicated with their siblings and if they have gone for screening. We would also find out which method did they adopt to communicate with their siblings.
Study: NCT01708187

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clarix™1k graft
Description: Group 1 will have standard peroneal repair surgery with the addition of the Clarix™1k tissue.~Group 2 will have standard peroneal repair surgery without the use of the Clarix™1k tissue.
Study: NCT00810160

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ProlactPlus
Description: Group 1 infants will be fed a concentration of Permeate mixed with formula. The ProlactPlus will be increased each week as follows: week 1 95:5 (formula:ProlactPlus), week 2 90:10, week 3 85:15, week 4 80:20, and week 5 75:25. Caloric content is roughly as follows: week 1 21 cal/oz, week 2 22 cal/oz, week 3 23 cal/oz, week 4 24 cal/oz, and week 5 25 cal/oz.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GOS galacto-oligosaccharides
Description: Group 2 infants will have their formula supplemented with galacto-oligosaccharides (GOS) for each feeding as follows: week 1 0.25 g/dL, week 2 0.5 g/dL, week 3 1.0 g/dL, week 4 1.5 g/dL, and week 5 2.0 g/dL.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium infantis
Description: Group 3 infants will have their formula supplemented with B. infantis twice daily increasing the dose each week as follows: week 1 5x107, week 2 1.5x108, week 3 4.5x108, week 4 1.4x109, and week 5 4.2x109.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium animalis
Description: Group 4 infants will have their formula supplemented with B. animalis twice daily increasing the dose each week as follows: week 1 5x107, week 2 1.5x108, week 3 4.5x108, week 4 1.4x109, and week 5 4.2x109.
Study: NCT00942708

Intervention type: DRUG
Group type: OTHER
Intervention: Fluoxetine
Description: Total dose How to take:~Week 1-2 20 mg daily Week 3-4 40 mg daily Week 5-6 40 mg BID Week 7-12 40mg BID
Study: NCT02243566

Intervention type: DRUG
Intervention: MicardisPlus®
Study: NCT01134484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: * INDUCTION THERAPY: 1.3 mg/sqm as a bolus i.v. injection on days 1, 4, 8 and 11 (3 courses, 21 days each)~* REMISSION CONSOLIDATION THERAPY: 1.3 mg/sqm as a bolus i.v. injection on days 1, 8, 15 and 22 (2 courses, 35 days each)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: * INDUCTION THERAPY: 100 mg/d on days 1-14, 200 mg/d on days 15-63 (in case of delay of HD-CTX , Thalidomide will be continued until the day before Cyclophosphamide as priming therapy for PBSC collection)~* AFTER PBSC COLLECTION: 100 mg/d from day after last PBSC collection until the day before first course of MEL-200~* AFTER FIRST TRANSPLANTATION: 100 mg/d from recovery of hematopoiesis until the day before the second course of MEL-200~* REMISSION CONSOLIDATION THERAPY (starting 3 months after the second autologous transplantation): 100 mg/d days 1-70

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: * INDUCTION THERAPY: 100 mg/d on days 1-14, 200 mg/d on days 15-63 (in case of delay of HD-CTX , Thalidomide will be continued until the day before Cyclophosphamide as priming therapy for PBSC collection)~* AFTER PBSC COLLECTION: 100 mg/d from day after last PBSC collection until the day before first course of MEL-200~* AFTER FIRST TRANSPLANTATION: 100 mg/d from recovery of hematopoiesis until the day before the second course of MEL-200~* REMISSION CONSOLIDATION THERAPY (starting 3 months after the second autologous transplantation): 100 mg/d days 1-70
Study: NCT02722187

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic varicocelectomy
Study: NCT00477451

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled placebo
Description: Inhaled Staccato Alprazolam Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled alprazolam 1 mg
Description: Inhaled Staccato Alprazolam 1 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled alprazolam 1 mg
Description: Inhaled Staccato Alprazolam 1 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled alprazolam 2 mg
Description: Inhaled Staccato Alprazolam 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV doxapram
Description: 0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV doxapram
Description: 0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV doxapram
Description: 0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV doxapram
Description: 0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo
Study: NCT02551848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Study: NCT01964365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cresto 20mg
Description: tablet, rosuvastatin 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibric acid 135mg
Description: capsule, fenofibric acid 135mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cresto 20mg, Fenofibric acid 135mg
Description: rosuvastatin 20mg, Fenofibric acid 135mg
Study: NCT04155385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement
Description: The measurement system collects information about patients' treatment progress and goals in key areas that are associated with long-term clinical outcomes (e.g., substance use, craving, coping skills, self-efficacy, life satisfaction, depression). Patients complete the measure up to once per week for up to six months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measurement
Description: The measurement system collects information about patients' treatment progress and goals in key areas that are associated with long-term clinical outcomes (e.g., substance use, craving, coping skills, self-efficacy, life satisfaction, depression). Patients complete the measure up to once per week for up to six months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feedback
Description: The feedback system is a web-based dashboard that displays current and historical results in each of the outcome and goal domains that is measured; it is available to addiction treatment clinicians who are working with patients enrolled in the study.
Study: NCT02730247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramucirumab
Description: it is administered through a vein in the arm as a 60 minute infusion at a dose of 8 mg/kg on days 1 and 15 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: it is administered through a vein in the arm as a 30 minute infusion at a dose of 100 mg/m2 on days 1, 8 and 15 of a 28 day cycle.
Study: NCT00743080

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy and supracervical hysterectomy with GYNECARE MORCELLEX
Description: Laparoscopic myomectomy with GYNECARE MORCELLEX: Laparoscopic approach. Longitudinal incision close to the midline of myoma. Identification of cleavage plane. Enucleation of myoma. Suturing myometrial. Removal of myoma with a automatic morcellator (GYNECARE MORCELLEX).~Laparoscopic supracervical hysterectomy using GYNECARE MORCELLEX: Laparoscopic approach. Use of bipolar diathermy and scissor starting with the round ligament and then the utero-ovarian ligament, otherwise the infundibulopelvic ligament in case of removal of adnexa. Identification, desiccation with polar diathermy, and transection of the uterine vessels. Repetition of the procedure on the contra-lateral side. Opening of vagina just below uterine vessels using an unipolar needle. Removal of uterus by means of GYNECARE MORCELLEX. Abdominal cavity irrigation.
Study: NCT04224558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Stem Cell Mobilization: Infused according to institutional guidelines;~Post-PBSC Infusion Conditioning: Mesna provided with Cytoxan according to institutional protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Stem Cell Mobilization:~Cyclophosphamide (CY) infused intravenously over 1 hour: 50 mg/kg (25 mg/kg/day on 2 consecutive days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Stem Cell Mobilization: Filgrastim (G-CSF) 10 mcg/kg SC will start 5 days after the last dose of CY and will end the day before the last leukapheresis;~Post-PBSC Infusion Conditioning: Filgrastim administered intravenously 5 mcg/kg IV starting day + 5, continue until ANC of \>1000/μL

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis catheter placement
Description: Subjects will require placement of an Apheresis catheter by Intervention Radiologists on the day of collection of stem cells.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Leukapheresis will be performed on a continuous flow separator machine according to institutional guidelines to target 3-8 x 10\^6 CD34+ cells/kg body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Preparative/Conditioning Regime Fludarabine given as 30 mg/m2 per dose x 4 days, beginning on day -6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Preparative/Conditioning Regime r-ATG pre-medication according to institutional guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Preparative/Conditioning Regime r-ATG premedication according to institutional guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Preparative/Conditioning Regime r-ATG premedication according to institutional guidlines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin (rabbit)
Description: Preparative/Conditioning Regime r-ATG administered intravenously: 2.5 mg/kg/dose IV over 6 hours on specified days (day -6,-4,-2); ); total 3 doses=7.5 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lymphocyte immune globulin
Description: Preparative/Conditioning Regime In patients who develop severe allergic reactions to rATG (Thymoglobulin), it may be substituted by horse ATG (hATG, ATGAM, Pharmacia \& Upjohn, Kalamazoo, MI). The recommended dose of hATG is 25 mg/kg/day for 3 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Infusion
Description: PBSC (peripheral blood stem cell) infusion on day 0 as per institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: Post-PBSC Infusion Conditioning Cytoxan infused intravenously: 50mg/kg/day x 2 days. Infused over 2 hours with adequate hydration or according to institutional guidelines.
Study: NCT01809366

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: seminal plasma insemination

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: seminal plasma insemination